How long does Botox last? Onset, peak, and normal waning

Cosmetic BOTOX has a gradual timeline, not a guaranteed expiration date. Many people notice a change within several days, while the American Academy of Dermatology describes cosmetic improvement as lasting about three to four months, sometimes longer. FDA studies measured particular facial-line responses at set visits; they do not predict the day one person’s movement will return. ^{1 2}

The useful question is not simply “Did it last four months?” It is: which product was used, for which moving line, what changed from baseline, and when did that same movement return? That record makes a follow-up more informative than comparing two unrelated social-media timelines.

Three clocks describe one treatment

An appointment date starts several different clocks. Mixing them makes a normal course look like failure, or makes a study result sound like a promise.

The AAD says most people see results within three to seven days. That is a general expectation for botulinum toxin therapy, not a deadline by which an individual must show a particular degree of change. ² A static crease visible even when the muscle is relaxed is also not the same endpoint as movement at maximum frown or smile. If a dynamic line improves but an etched line remains, the drug may have affected its intended muscle without erasing a different skin feature.

What the FDA’s day-by-day data actually show

The current BOTOX Cosmetic label includes two placebo-controlled studies for moderate to severe glabellar lines—the vertical frown lines between the brows. Investigators graded severity at maximum frown, and the label reports the share rated none or mild at successive visits. In the combined treated group, the reported rates were 74% at day 7, 80% at day 30, 70% at day 60, 48% at day 90, and 25% at day 120. ¹

Those are group-level responder rates for a defined dose, anatomy, population, and rating scale. Day 120 does not mean that exactly 25% of consumers still feel an effect or that everyone else abruptly returns to baseline. The study definition counts a person above the “mild” threshold as a nonresponder even if they have some improvement. It also does not describe a forehead, crow’s-foot, lip-flip, or another product’s duration.

The label’s lateral-canthal and forehead studies have their own schedules and measures. They are more useful for understanding how a response can rise and then taper than for transferring a single survival curve to every face. This is why a clinic’s unqualified “lasts six months” promise is less informative than a product-, site-, and goal-specific conversation.

A practical way to record normal waning

Before a visit, the clinician can document the line at rest and at the movement being treated. At follow-up, the same lighting, angle, and expression are more useful than comparing a posed photograph with an unposed one. The record should distinguish:

1. No meaningful change from baseline: a different question from how long a response lasted.
2. A noticeable response followed by gradual movement return: often the ordinary temporary course.
3. Movement stayed reduced, but a line remains at rest: possibly a different target or skin-texture question rather than failure of muscle relaxation.
4. An uneven or unexpected change: a reason to ask the treating clinician to evaluate the specific finding rather than guessing from a generic timeline.

Write down the exact brand, treated muscles or labeled regions, units recorded by the practice, treatment date, first noticed change, and the movement that later returned. BOTOX Cosmetic potency units are product-specific and cannot be converted directly into another botulinum toxin product’s units. ¹ The product comparison explains that separate question; it cannot turn one brand’s trial into a personalized calendar for another.

What changes the interpretation of “short-lived”

A short interval can reflect an early measurement, a different aesthetic goal, a different anatomy, or a genuinely smaller response. It is not, by itself, evidence of antibodies or a faulty vial. A person who wants full stillness will call the return of slight movement “wearing off” sooner than someone whose goal was softening without losing expression. The product label, clinical plan, and patient’s goal should be read together.

In the FDA trials, the population and endpoint were deliberately narrow. Someone evaluating horizontal forehead movement, crow’s feet at smile, or a use outside labeled indications should not treat the glabellar percentages as a personal benchmark. The AAD’s approximate three-to-four-month description is a useful planning range, but “average” cannot replace a record of the actual response. ^{1 2}

Similarly, the effect on sweating follows a different anatomy, injection approach, and duration discussion. The AAD says underarm sweating relief may last longer than facial wrinkle improvement. ³ A patient searching for cosmetic timing should not borrow the hyperhidrosis timeline.

If there was little or no response after the clinic’s planned assessment interval, the next step is a product and treatment-record review. The nonresponse guide covers that different question. It should not be invoked just because a documented improvement later waned.

Make the follow-up question answerable

Ask the treating practice to describe its planned assessment point and what it will compare: movement at a specified expression, line grade, symmetry, photographs, or a goal recorded at consultation. Ask whether a follow-up visit is an evaluation only or also includes a separately priced adjustment. Do not book repeat treatment simply to match an internet interval; the clinician must assess the product label, treatment history, response, and goals.

If comparing South Florida providers, use the Botox provider lane to identify practices, then ask each for the same product, assessment, and follow-up terms. The observed offer page records advertised pricing bases, not expected duration. A good consultation can give you a specific way to judge your own response without turning a population average into a guarantee.